Biodesix (BDSX) Stock Price, News & Analysis

Company Overview

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Key Stats

• Today's Range: $0.71 to $0.75
• 50-Day Range: $0.71 to $1.49
• 52-Week Range: $0.64 to $2.04
• Volume: 168,867 shs
• Average Volume: 276,147 shs
• Market Capitalization: $105.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.95
• Consensus Rating: Buy

Biodesix Stock Analysis - MarketRank™

Biodesix scored higher than 62% of companies evaluated by MarketBeat, and ranked 406th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Biodesix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Biodesix has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biodesix are expected to grow in the coming year, from ($0.35) to ($0.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biodesix is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biodesix is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biodesix has a P/B Ratio of 14.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.17% of the float of Biodesix has been sold short.

Short Interest Ratio / Days to Cover

Biodesix has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biodesix has recently increased by 24.56%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biodesix does not currently pay a dividend.

Dividend Growth

Biodesix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.17% of the float of Biodesix has been sold short.

Short Interest Ratio / Days to Cover

Biodesix has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biodesix has recently increased by 24.56%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.00

News Sentiment

Biodesix has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Biodesix this week, compared to 1 article on an average week.

MarketBeat Follows

6 people have added Biodesix to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Biodesix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $118,406.00 in company stock.

Percentage Held by Insiders

69.20% of the stock of Biodesix is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 20.96% of the stock of Biodesix is held by institutions.

BDSX Stock Analysis - Frequently Asked Questions

How have BDSX shares performed this year?

Biodesix's stock was trading at $1.53 at the beginning of 2025. Since then, BDSX shares have decreased by 52.8% and is now trading at $0.7221.
View the best growth stocks for 2025 here.

How were Biodesix's earnings last quarter?

Biodesix, Inc. (NASDAQ:BDSX) issued its quarterly earnings data on Monday, March, 3rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. The company had revenue of $20.43 million for the quarter, compared to analyst estimates of $19.92 million. Biodesix had a negative trailing twelve-month return on equity of 275.79% and a negative net margin of 66.84%.

When did Biodesix IPO?

Biodesix (BDSX) raised $76 million in an IPO on Wednesday, October 28th 2020. The company issued 4,200,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Who are Biodesix's major shareholders?

Top institutional investors of Biodesix include AIGH Capital Management LLC (4.25%), Birchview Capital LP (3.84%), Silverarc Capital Management LLC (2.98%) and Farallon Capital Management LLC (2.62%). Insiders that own company stock include Jack W Schuler, John Patience, Scott Hutton, Robin Harper Cowie, Gary Anthony Pestano, Kieran O'kane, Robert William Georgantas III and Chris Vazquez.
View institutional ownership trends.

How do I buy shares of Biodesix?

Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biodesix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biodesix investors own include Broadcom (AVGO), NVIDIA (NVDA), Adobe (ADBE), Arista Networks (ANET), ServiceNow (NOW), CrowdStrike (CRWD) and Meta Platforms (META).

Company Calendar

• Last Earnings: 3/03/2025
• Today: 3/14/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:BDSX
• CIK: 1439725
• Web: www.biodesix.com
• Phone: 303-417-0500
• Fax: N/A
• Employees: 220
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.95
• High Stock Price Target: $3.00
• Low Stock Price Target: $2.80
• Potential Upside/Downside: +301.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-52,150,000.00
• Net Margins: -66.84%
• Pretax Margin: -66.84%
• Return on Equity: -275.79%
• Return on Assets: -43.05%

Debt

• Debt-to-Equity Ratio: 1.30
• Current Ratio: 3.40
• Quick Ratio: 3.40

Sales & Book Value

• Annual Sales: $71.32 million
• Price / Sales: 1.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.05 per share
• Price / Book: 14.70

Miscellaneous

• Outstanding Shares: 145,978,000
• Free Float: 44,804,000
• Market Cap: $107.29 million
• Optionable: Optionable
• Beta: 1.10